Table 2.
Clinical variables and use of oral antidiabetics at index date in total patient population and by age subgroup
| Clinical variables and OAD use | Age subgroups | Total patient population (N = 2709; 100%) | |
|---|---|---|---|
| 30–64 years (n = 1214; 44.8%) | ≥ 65 years (n = 1495; 55.2%) | ||
| HbA1c, % | |||
| Mean level (SD) | 9.5 (1.5) | 9.0 (1.1) | 9.2 (1.3) |
| Median level (95% CI) | 9.0 (9.4–9.6) | 8.7 (8.9–9.1) | 8.8 (9.1–9.3) |
| Percentage of patients with HbA1c of: | |||
| 8.0–8.9% (95% CI) | 49.3% (46.5–52.1%) | 63.6% (61.2–66.0%) | 57.2% (55.3–59.1%) |
| 9.0–9.9% (95% CI) | 25.3% (22.9–27.7%) | 23.7% (21.5–25.7%) | 24.4% (22.8–26.0%) |
| ≥ 10.0% (95% CI) | 25.4% (23.0–27.8%) | 12.7% (11.0–14.4%) | 18.4% (16.9–19.9%) |
| BMI, kg/m2 (SD; 95% CI) | 32.1 (0.9; 32.0–32.2) | 32.0 (1.0; 31.9–32.1) | 32.1 (0.9; 32.0–32.2) |
| OADs | |||
| Mean, n (SD) | 2.2 (0.4) | 2.4 (0.6) | 2.3 (0.5) |
| Median, n (95% CI) | 2.0 (2.1–2.3) | 2.0 (2.3–2.5) | 2.0 (2.2–2.4) |
| Percentage of patients with 2 OADs (95% CI) | 85.6% (83.6–87.6%) | 69.7% (67.4–72.0%) | 76.8% (75.2–78.4%) |
| Met + SU | 72.9% (70.4–75.4%) | 55.5% (53.0–58.0%) | 63.3% (61.4–65.0%) |
| Met + IDPP4 | 7.4% (5.9–8.9%) | 10.1% (8.6–11.6%) | 8.9% (7.8–10.0%) |
| Other combinations | 5.3% (4.0–6.6%) | 4.1% (3.1–5.1%) | 4.6% (3.8–5.4%) |
| Percentage of patients with 3 OADs (95% CI) | 13.3% (11.4–15.2%) | 24.9% (22.7–27.1%) | 19.7% (18.2–21.2%) |
| Met + SU + IDPP4 | 7.2% (5.7–8.7%) | 14.4% (12.6–16.2%) | 11.2% (10.0–12.4%) |
| Met + SU + glitazones | 5.7% (4.4–7.0%) | 10.2% (8.7–11.7%) | 8.2% (7.2–9.2%) |
| Other | 0.3% (0.0–0.6%) | 0.3% (0.0–0.5%) | 0.3% (0.1–0.5%) |
| Percentage of patients with 4 OADs (95%CI) | 1.2% (0.6–1.8) | 5.4% (4.3–6.5%) | 3.3% (2.9–4.3%) |
| Met + SU + glitazones + IDPP4 | 1.0% (0.4–1.6%) | 4.0% (3.0–5.0%) | 2.3% (1.7–2.9%) |
| Other combinations | 0.2% (0.0–0.6%) | 1.4% (0.8–2.0%) | 1.2% (0.8–1.6%) |
OAD oral antidiabetics, HbA1c glycosylated haemoglobin (%), BMI body mass index (kg/m2)
Met Metformin, SU sulfonylureas, IDDP4 dipeptyl peptidase 4 inhibitors
Values expressed as percentages, mean (SD: standard deviation), 95% CI; confidence interval